The omega-3 fatty acid, eicosapentaenoic acid (EPA), prevents the damaging effects of tumour necrosis factor (TNF)-alpha during murine skeletal muscle cell differentiation by Magee, P et al.
BioMed CentralLipids in Health and Disease
ssOpen AcceResearch
The omega-3 fatty acid, eicosapentaenoic acid (EPA), prevents the 
damaging effects of tumour necrosis factor (TNF)-alpha during 
murine skeletal muscle cell differentiation
Peter Magee1, Stephen Pearson2 and Jeremy Allen*1
Address: 1Biomedical Sciences Research Institute, University of Salford, Manchester, M5 4WT, UK and 2Centre for Rehabilitation and Human 
Performance Research, University of Salford, Manchester, M5 4WT, UK
Email: Peter Magee - p.magee@pgr.salford.ac.uk; Stephen Pearson - s.pearson@salford.ac.uk; Jeremy Allen* - j.t.allen@salford.ac.uk
* Corresponding author    
Abstract
Background: Eicosapentaenoic acid (EPA) is a -3 polyunsaturated fatty acid with anti-
inflammatory and anti-cachetic properties that may have potential benefits with regards to skeletal
muscle atrophy conditions where inflammation is present. It is also reported that pathologic levels
of the pro-inflammatory cytokine tumour necrosis factor (TNF)-α are associated with muscle
wasting, exerted through inhibition of myogenic differentiation and enhanced apoptosis. These
findings led us to hypothesize that EPA may have a protective effect against skeletal muscle damage
induced by the actions of TNF-α.
Results: The deleterious effects of TNF-α on C2C12 myogenesis were completely inhibited by
co-treatment with EPA. Thus, EPA prevented the TNF-mediated loss of MyHC expression and
significantly increased myogenic fusion (p < 0.05) and myotube diameter (p < 0.05) indices back to
control levels. EPA protective activity was associated with blocking cell death pathways as EPA
completely attenuated TNF-mediated increases in caspase-8 activity (p < 0.05) and cellular necrosis
(p < 0.05) back to their respective control levels. EPA alone significantly reduced spontaneous
apoptosis and necrosis of differentiating myotubes (p < 0.001 and p < 0.05, respectively). A 2 hour
pre-treatment with EPA, prior to treatment with TNF alone, gave similar results.
Conclusion: In conclusion, EPA has a protective action against the damaging effects of TNF-α on
C2C12 myogenesis. These findings support further investigations of EPA as a potential therapeutic
agent during skeletal muscle regeneration following injury.
Background
Skeletal muscle can be affected by a number of potentially
damaging conditions which lead to muscle atrophy. These
conditions can include ageing and disease states. With
ageing, muscle wasting occurs which is a chronic condi-
tion complicated by multitude of factors. A number of
models have been suggested to explain the ageing related
loss of muscle tissue, amongst which is the immunologi-
cal theory. Here changes in DNA methylation and muta-
tion of the somatic cells (epigenetic, chromosome
abnormalities) could lead to increases in autocatalytic
processes which ultimately leads to self destruction.
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immune inflammatory response may lead to muscle dam-
age and sarcopenia [1].
Disease states can be both chronic and acute, but both
ageing and disease can share some common factors. In
particular, inflammation has been suggested to be present
in a number of disease states associated with muscle atro-
phy, such as cancer, heart failure, rheumatoid arthritis,
chronic obstructive pulmonary disease, HIV/AIDS, and
also ageing related muscle wasting. Associated with this
response are pro-inflammatory cytokines, such as tumour
necrosis factor (TNF)-α that are commonly present at ele-
vated levels (0.5–10 ng/ml) during disease[2-5]. A bimo-
dal response to TNF-α has been reported. Whereas,
pathologic levels of TNF-α have been identified as playing
a significant role in the mechanisms associated with skel-
etal muscle wasting [6], low physiological concentrations
(0.05 ng/ml) appear to activate myogenesis [7]. A number
of previous studies, both in vitro and in vivo have shown
that raised levels of TNF-α causes increased muscle loss [8-
12]. At least two mechanisms may account for the skeletal
muscle-wasting effects of TNF-α: inhibition of myogenesis
in myoblasts; apoptosis of myoblasts and myotubes. A
number of in vitro studies suggest the effects of TNF-α are
specific to the stage of myotube differentiation at the time
of administration. Thus, delivery of TNF-α to primary
human myoblasts or murine C2C12 myoblasts inhibits
myosin heavy chain (MyHC) expression and myogenic
differentiation [13-16] whereas treatment of differenti-
ated myotubes with TNF-α appears to have marginal
effects on their total or MyHC protein content [13,16].
However, a more recent finding suggests differentiated
(C2C12) myotubes are susceptible to TNF-α-mediated
apoptosis [17].
The cellular action of TNF-α is complex and is exerted
through a number of signalling pathways in skeletal mus-
cle. Recent findings suggest that low levels of TNF-α are
required for myoblast proliferation and this aspect of
myogenesis is regulated by activation of p38 mitogen-acti-
vated protein kinase (MAPK) [7]. In contrast, at patho-
logic levels of TNF-α, high levels of myoblast apoptosis
are observed and myogenic differentiation is inhibited
[18,19]. The apoptosis observed during differentiation of
myoblasts is characterized by initial NF-κB activation
[16,19] and activation of caspase-8 [19]. In differentiated
myotubes, pathologic levels of TNF-α have been found to
increase total and myofibrillar protein content through
stimulation of MAPK pathways [20], however these ana-
bolic effects are counteracted by findings that, at high lev-
els, TNF-α also induces myotube apoptosis which is
characterized by enhanced caspase-3 activity [17].
A number of experimental and clinical studies have
described potential health benefits for -3 polyunsaturated
fatty acids (PUFA), notably in reducing the incidence of
cardiovascular disease [21]. Eicosapentaenoic acid (EPA)
is a -3 PUFA with demonstrable anti-inflammatory activi-
ties that may have potential benefits with regards to
atrophic skeletal muscle conditions [22]. In this regard, it
has been reported that in a murine model of cachexia, EPA
treatment caused a reduction in the rate at which skeletal
muscle protein was lost [23] and that preservation of skel-
etal muscle protein was due to downregulation of the
ubiquitin-proteasome proteolytic pathway [24]. EPA
treatment has also been shown to attenuate the proteo-
lytic and apoptotic effects of a cachectic factor in fully dif-
ferentiated myotubes from the murine C2C12
myogenesis model, although TNF-α was not used in these
studies [25,26].
These findings led us to hypothesize that EPA may have a
protective effect against skeletal muscle damage induced
by pro-inflammatory TNF-α. Hence, the aims of the
present study were to utilise TNF-α in a damage model of
murine C2C12 myogenic differentiation and to deter-
mine whether EPA treatment was able to reduce the dele-
terious effects of TNF-α on skeletal muscle cell
differentiation. We evaluated the responses of differentiat-
ing cells to TNF-α and EPA treatments by morphological
criteria and by expression of MyHC and quantified their
effects on apoptosis by measuring caspase-8 activity.
Results
Effect of TNF-α and EPA on Myogenic Differentiation
Under permissive conditions in a low-serum culture
medium (DM), C2C12 myoblasts will differentiate to
form myotubes. After 5 days following initiation of differ-
entiation by incubation in DM, the morphological
appearance of formed myotubes was examined (figure 1).
Under control growth conditions in DM, fully formed
myotubes were prominent throughout (figure 1A). EPA
alone, either administered as a 2 h pre-treatment in DM
(figure 1B), or continuously throughout the duration of
the experiment (figure 1C), had no apparent effect on the
normal pattern of myogenesis; myotubes were formed,
their rate of differentiation was similar to controls (data
not shown) and they appeared morphologically indistinct
from controls (figure 1A); the timing of the appearance of
MyHC (data not shown) and its pattern of expression as
visualised by immunocytochemistry, was also similar to
that of controls (figure 1A). Previous studies have exam-
ined the effects of the inflammatory cytokine TNF-α on
myotube formation and established that high concentra-
tions, typically found in chronic disease states, are able to
reversibly inhibit myotube formation. We first confirmed
that TNF-α (20 ng/ml) markedly inhibited the formation
of myotubes (figure 1D). We then examined the effect ofPage 2 of 11
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EPA ameliorates the effects of TNF-α on differentiating myotube appearance and MyHC expressionFigure 1
EPA ameliorates the effects of TNF-α on differentiating myotube appearance and MyHC expression. C2C12 
cells were induced to differentiate in DM in the presence or absence of TNF-α (20 ng/ml). EPA (50 μM) was added together 
with TNF-α as a co-treatment (EPA). Alternatively, for some experiments EPA was administered alone for a 2 hour pre-treat-
ment (pEPA) after which it was withdrawn and replaced by TNF-α alone in DM. Incubations were continued for 5 days in DM 
with replenishment of EPA and TNF-α at media changes. Representative images show immunofluorescence detection of Alexa-
Fluor546 conjugated anti-MF20 antibody against MyHC (pink) and DAPI counterstained nuclei (blue) for various treatments 
with EPA and TNF-α. Control treatments are shown in the left panel images and TNF-α treatments in the right panel images. 
Calibration bars are 100 μm.
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Lipids in Health and Disease 2008, 7:24 http://www.lipidworld.com/content/7/1/2450 μM EPA co-treatment together with TNF-α on myotube
differentiation. Data shown in figure 1F indicate that EPA
was able to prevent the deleterious effects of TNF-α on
myotube differentiation and the pattern of MyHC expres-
sion. Furthermore, a single dose of EPA given for 2 h, prior
to treatment with TNF-α alone, was sufficient to be able to
largely prevent these inhibitory actions of TNF-α on myo-
genesis (figure 1E).
These protective effects of EPA were further evidenced
when we investigated morphological parameters of myo-
genesis; namely myoblast fusion (Figure 2) and myotube
size (Figure 3). The results of a myoblast fusion index
(MI) presented in figure 2A show that TNF-α significantly
inhibited (p < 0.05) MI after 48 hours and at 5 days, com-
pared to control treatment in DM. EPA alone had no sig-
nificant effect on the MI. EPA also had no effect on the rate
of differentiation as indicated by a comparison between
EPA and control after 48 hours of treatment. Treatment
with EPA, either as a pre-treatment or as a co-treatment
with TNF-α, improved the MI with additional benefit
derived from a longer incubation with EPA. Following
pre-incubation with EPA, the MI was partially restored
with levels significantly higher than with TNF-α, reaching
40% (p < 0.05) and 50% (p < 0.05), compared to 5% and
30% for TNF-α, after 48 hours and 5 days respectively.
When EPA was added as a co-treatment with TNF-α, the
MI was partially restored after 48 hours but was fully
restored to control levels of 70% by 5 days (NS v. control).
In figure 2B, data are shown for the average number of
nuclei found per myotube after 5 days, as a marker of the
heterogeneity of myotube size. Myotubes treated with
TNF-α showed the greatest uniformity but were much
smaller and poorly developed, with >90% having <6
nuclei, significantly higher than controls at 20% (p <
0.001). EPA co-treatment completely prevented these
effects of TNF-α and the size distribution of myotubes was
not significantly different from that of controls. Here,
most myotubes were large with 40% having >10 nuclei,
compared to 0% with TNF-α treatment (p < 0.001). EPA
pre-treatment was able to partially reverse the effects of
TNF-α and here myotubes were more heterogeneous, with
proportionately more smaller myotubes and fewer large
myotubes compared to controls (p < 0.001). The results
presented in figure 3 show that TNF-α significantly inhib-
its myotube size (p < 0.05), reducing mean diameter after
5 days from approximately 27 μm to 8 μm, compared to
control. EPA alone did not significantly alter myotube
size. However, treatment of differentiating myotubes with
EPA, either as a pre-treatment or as a co-treatment, with
TNF-α improved myotube size. Following pre-incubation
with EPA, myotube size was significantly higher than with
TNF-α (p < 0.05), reaching approximately 20 μm. When
EPA was added as a co-treatment with TNF-α, myotube
size was also significantly increased compared to TNF-α
(p < 0.05) reaching approximately 24 μm, a size not sig-
nificantly different from controls (NS v. control).
Effects of EPA on cellular necrosis
Since it has been reported that non-esterified free fatty
acids can have cytotoxic effects on cultured cells [27], we
used EPA conjugated with BSA in all studies. To investi-
gate the effects of EPA on cell death in differentiating
C2C12 myotubes, several complementary assays were
performed. A commercial CellTiter-Blue cytotoxicity assay
was performed to determine cell death over 5 days of cul-
ture in DM. This assay does not distinguish between the
mode of cell death i.e. apoptosis or necrosis. As shown in
figure 4A, 50 μM EPA significantly reduced (p < 0.05) cell
death in DM, compared to controls. These data suggested
EPA was protective against cell death during myotube for-
mation. Using an alternative approach of dye exclusion
(Trypan Blue) which will not detect cells in the earlier
stages of apoptosis with intact cell membranes, we con-
firmed that EPA significantly reduced cellular necrosis (p
< 0.05) at an earlier time-point (48 h) from initiation of
differentiation (figure 4B). We next examined whether
TNF-α induced cellular necrosis in this model and if EPA
treatment could prevent this activity (figure 4B). Prelimi-
nary experiments suggested that significant TNF-α-medi-
ated cell necrosis became apparent by 48 hours (data not
shown), so this time-point was adopted for the remainder
of the experiment. TNF-α (20 ng/ml) induced significant
(p < 0.05) cellular necrosis by 48 hours after initiation of
differentiation, compared to control with almost 50% of
cells assessed as non-viable. EPA treatment was found to
have a protective effect against the TNF-α-induced
increase in necrosis. Co-treatment with EPA completely
abolished (p < 0.05) the effects of TNF-α, compared to
control (Fig 4B), whereas a 2 hour pre-incubation of cells
with EPA, prior to treatment with TNF-α alone, was suffi-
cient to partially but significantly reduce (p < 0.05) the
TNF-α-induced damage, compared to TNF-α alone (Fig
4B).
Effect of EPA on apoptosis
Further investigation of the apparent protective effect of
EPA against the inhibition of myogenesis in differentiat-
ing C2C12 myotubes by TNF-α was carried out to deter-
mine whether protection against apoptosis was conferred
by EPA. We first examined whether EPA had an effect on
baseline levels of apoptosis. When 50 μM EPA was admin-
istered to C2C12 cells in DM there was apparent suppres-
sion of apoptosis measured after 5 days indicated by
Hoechst 33258 staining (figure 5A). A calculated apopto-
sis index (AI) showed a significant >50% reduction (p <
0.001) in the proportion of apoptotic cells from approxi-
mately 20% to 6% following treatment with EPA, com-
pared to untreated controls (figure 5B). To confirm these
findings and to try and determine the nature of the protec-Page 4 of 11
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cial assay (Caspase Glo-8, Promega) because in a similar
model system, transfer of C2 myoblasts to DM has previ-
ously been reported to provoke spontaneous apoptosis
mediated by caspase-8 activity [19]. Treatment of cells in
DM with 50 μM EPA significantly inhibited (p < 0.05) the
caspase-8 activity associated with spontaneous apoptosis,
compared to untreated controls (figure 5C). We next
investigated whether EPA could inhibit TNF-α-mediated
apoptosis. Since TNF-α-induced apoptosis is associated
with caspase-8 activation, by mechanisms downstream of
the TNF-α receptor 1 (TNFR1) in differentiating myob-
lasts [18,19,28], we evaluated caspase-8 activity in
response to treatment with TNF-α, and with EPA to deter-
mine whether EPA could block the caspase-8 activity asso-
ciated with TNF-α-induced apoptosis (figure 6). In
response to TNF-α (20 ng/ml) there was a significant (p <
0.001) increase in caspase-8 activity by 24 or 48 hours in
DM, compared to respective untreated controls. EPA treat-
ment was found to block the TNF-α-induced increase in
caspase-8 activation at both of these time-points. Co-treat-
ment with EPA completely blocked (p < 0.05) the effects
of TNF-α on caspase-8 activity. A similar significant (p <
0.05) protective effect of EPA was obtained when cells
were instead pre-incubated for 2 hours with EPA, prior to
treatment with TNF-α alone.
Discussion
It has previously been suggested that muscle cells exposed
to TNF-∝ during differentiation will be adversely affected.
This study examined the potential for EPA to protect skel-
etal muscle cells during their differentiation from myob-
lasts to myotubes in an inflammatory damage model. The
main findings of this study were that EPA has a significant
and protective effect on myogenesis in a murine C2C12
model of muscle damage. Undifferentiated C2C12 myob-
lasts, the in vitro equivalent of satellite cells, can be
induced to differentiate into non-proliferating, multinu-
cleated, fully differentiated myotubes over a period of
days in the presence of a reduced-serum growth medium.
Using this model, or primary human myoblasts, it has
been shown that TNF-α has differential effects according
to the developmental stage of myogenesis and these are
mediated through alternative mechanisms that inhibit
myotube formation or that induce myoblast and myotube
apoptosis. Thus, in cultured differentiating primary
human or C2C12 myoblasts, addition of TNF-α com-
pletely inhibits MyHC expression and myogenic differen-
tiation [13,14,29,30]. In this study, using the C2C12
model, we observed reductions in indices of myogenesis
in response to TNF-α treatment, including myotube size,
myoblast fusion index and expression of MyHC. How-
ever, the presence of EPA blocked the TNF-induced inhi-
bition of MyHC expression. EPA treatment by itself does
not seem, for the limited range of markers we have meas-
ured, to significantly affect the differentiation process
EPA reverses TNF-α-mediated interference with myoblast fusionFigu  2
EPA reverses TNF-α-mediated interference with 
myoblast fusion. C2C12 cells were induced to differentiate 
in the presence or absence of TNF-α (20 ng/ml) and EPA (50 
μM). EPA was added together with TNF-α as a co-treatment 
(EPA+TNF) or, alternatively EPA was administered alone for 
a 2 hour pre-treatment after which it was withdrawn and 
replaced by TNF-α alone in DM (pEPA+TNF). Incubations 
were continued for 48 hours or 5 days in DM with replenish-
ment of EPA and TNF-α at media changes. A myogenic index 
(MI) of fusion was calculated from ten images of randomly 
chosen microscope fields for DAPI and MyHC stained cells 
from each treatment. The total number of nuclei and the 
number of nuclei incorporated into myotubes were counted 
(A). Myotube size heterogeneity was evaluated after 5 days 
from the same images by calculating the number of nuclei per 
myotube and classifying them arbitrarily to categories of 
small (2–5 nuclei), medium (6–9 nuclei) or large (>10 nuclei) 
myotubes (B). Data are expressed as means ± standard error 
of mean (SEM) from 3 independent experiments (*p < 0.05 v. 
respective control; #p < 0.05 v. TNF-α; **NS v. control).
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speculate that this could potentially enhance differentia-
tion by increasing the pool of viable myonuclei available
that can contribute to myotube formation. Our results
showed a significant (p < 0.05) effect of EPA on the reduc-
tion of myogenesis caused by TNF-α, that was evident in
both the continuous and pre-incubation conditions.
Alone, TNF-α caused a 9-fold decrease in MI after 48
hours whereas by 5 days this was only 2-fold. These data
are consistent with reports that more mature myotubes
are less susceptible to the damaging effects of TNF-α on
myogenesis [13,14]. In conjunction with this observation,
the fusion index was markedly improved in the presence
of EPA, such that differentiating myotubes continuously
dosed with both TNF-α and EPA were significantly differ-
ent to those dosed with TNF-α alone with MI showing no
alteration from control levels of 70% by day 5. Similar
effects were noted on indices of myotube size whereby
myotube diameter and heterogeneity of size closely
matched those of controls. EPA delivered as a short pre-
treatment was still effective against TNF-α but these
parameters were only partially restored to their respective
control levels. This observed increased efficacy of EPA co-
treatment most likely reflects the continuous availability
of EPA during the experiments and was also a feature in
the viability experiments and in apoptosis experiments
and is discussed further below.
Following TNF-α treatment, there is an initial 24 h period
of myoblast proliferation associated with transient NF-κB
and Jun kinases (JNK) 1 and 2 activation, followed by
induction of apoptosis [19]. More recent findings show
direct apoptotic activity of TNF-α on formed myotubes
mediated by caspase-3 activation [17]. Here, our data
have shown that caspase-8 activation is associated with
the prevention of normal C2C12 myotube differentiation
by TNF-α. Although this is consistent with previous find-
ings showing that caspase-8 activation was an essential
requirement for TNF-α induced apoptosis in this model
[19], a mechanism most likely mediated through the TNF-
receptor 1 (TNF-R1) signalling complex, this requires fur-
ther confirmation. In the background it was stated that
TNF-α can inhibit differentiation in at least two ways;
inhibition of myogenesis in differentiating myoblasts;
induction of apoptosis of myoblasts and myotubes. Our
data support a contribution to enhanced differentiation
by decreasing TNF-mediated signalling through pathways
involving the activation of caspase-8. Our data showed
that the effects of TNF-α on caspase-8 were ablated follow-
ing both a 2 hour pre incubation and continuous admin-
istration of 50 μM EPA, suggesting EPA as a potent
inhibitor of TNF-α activated caspase-8 activity. In support
of our findings, in fully differentiated C2C12 myotubes
PIF-mediated caspase activation and apoptosis can be
attenuated by EPA pre-treatment [26]. Although TNF-α
was not used in the reported study, those findings lend
support to a view that the protective actions of EPA may
be independent of differentiation status, although further
studies will be required to confirm this. There are several
previous reports that docosahexaenoic acid (DHA) the
other primary -3 PUFA found in fish oils, attenuates
human monocyte apoptosis or murine fibrosarcoma
necrosis induced by TNF-α [27,31]. In general agreement
with these studies it was observed here that EPA treatment
had a beneficial effect against the TNF-α-induced increase
in necrosis. Whereby, EPA completely eliminated the
effects of TNF-α on cell death, and a 2 hour pre-treatment
of cells with EPA, prior to TNF-α dosing, was sufficient to
partially, but significantly reduce (p < 0.05) the TNF-α-
induced damage, compared to TNF-α alone. However, as
discussed above, the pre-treatment was sufficient to block
caspase-8 activity induced by TNF-α. This may reflect an
increased susceptibility of pathways associated specifi-
cally with caspase activation, to EPA inhibition, although
this will require further clarification. A 2 hour pre-treat-
ment with EPA has been used previously and found to
effectively inhibit apoptosis in fully differentiated myo-
EPA prevents a TNF-α-mediated reduction in myotube sizeFigure 3
EPA prevents a TNF-α-mediated reduction in myo-
tube size. C2C12 cells were induced to differentiate in the 
presence or absence of TNF-α (20 ng/ml) and EPA (50 μM). 
EPA was added together with TNF-α as a co-treatment 
(EPA+TNF) or, alternatively EPA was administered alone for 
a 2 hour pre-treatment after which it was withdrawn and 
replaced by TNF-α alone in DM (pEPA+TNF). Incubations 
were continued for 5 days in DM with replenishment of EPA 
and TNF-α at media changes. Myotube diameters were cal-
culated for DAPI and MyHC stained cells from each treat-
ment. Data are expressed as means ± standard error of 
mean (SEM) from 3 independent experiments (*p < 0.05 v. 
control; #p < 0.05 v. TNF-α; **NS v. control).
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vary from 30 minutes [32] to 24 hours pre-treatment
[27,33,34]. 24 hours EPA treatment was sufficient to sig-
nificantly alter the membrane lipid composition of mac-
rophages; EPA increased from 0.3 to 22.7% and AA fell
from 7.3 to 2.0% [35]. It is possible to speculate that
increasing the pre-treatment time from 2 hours up to 24
hours would increase the efficacy of EPA.
A definitive explanation for the ability of EPA to protect
differentiating myotubes from the inhibitory effects of
TNF-α is currently lacking. The most widely accepted
proposition for its anti-inflammatory efficacy is that EPA
changes the membrane phospholipid pool, becoming
readily incorporated into the cell membrane at the
expense of AA [22,36]. A possible link between our obser-
vations and with the activities of EPA reported above can
be made by considering that AA is released from cells
undergoing TNF-α-mediated apoptosis and that cytoplas-
mic (c) phospholipase A2 (PLA2) plays a major role in this
process [37]. TNF-α mediates the activation of cPLA2 via
the TNF-R1. Interestingly, TNF-R1 expression is also
upregulated by AA and can be inhibited by -3 PUFAs
including EPA [32]. Signalling via the TNF-R1 death
receptor is very complex. Simplistically, recruitment of
death domain-containing intracellular adaptor molecules
at the receptor site transduces apoptotic or survival sig-
nals. Thus, recruitment of TNF-R associated death domain
(TRADD) and Fas associated death domain (FADD) mol-
ecules leads to interactions with, and subsequent activa-
tion of, pro-caspase molecules and apoptosis.
Alternatively, recruitment of TRAF1 and TRAF2 and their
interaction with TRADD leads to activation of Jun N-ter-
minal kinase (JNK) and NF-κB which prevents caspase-8
activation and apoptosis [38]. Since our data showed EPA
inhibits caspase-8 activity it would be interesting to inves-
tigate this further. Our data also showed reductions in
indices of myogenesis in response to TNF-α treatment,
including myotube size, myoblast fusion index and
expression of MyHC. It has been reported that inhibition
of muscle specific protein expression during C2C12 myo-
genic differentiation by TNF-α is dependent on activation
of NF-κB which is a major regulator of inflammatory
genes [16,6]. PUFA regulation of gene transcription fac-
tors is an emerging area of study and differential effects
have been reported; whereas -3 PUFAs inhibit, -6 PUFAs
stimulate, NF-κB activation [39]. Similarly, in differenti-
ated human myotubes it was found that saturated fatty
acids (palmitate), but not PUFAs, activate NF-κB [40]. The
ability of EPA to inhibit NF-κB activation is documented
by several studies and seems to involve decreased phos-
phorylation and thus reduced degradation of the inhibi-
tory IκB complex [22,35]. It has also been suggested that
the highly polyunsaturated EPA could be readily oxidised
and that oxidised EPA then interferes with NF-κB activa-
EPA ameliorates baseline and TNF-α-induced cellular necro-sisFigure 4
EPA ameliorates baseline and TNF-α-induced cellu-
lar necrosis. Any potential cytotoxic effect of EPA on 
C2C12 myotube formation was investigated after 5 days fol-
lowing induction of differentiation by DM using a CellTiter 
Blue assay to detect all non-viable cells (A). The effect of 
TNF-α (20 ng/ml) on cellular necrosis and the ability of EPA 
to block this activity were also assessed by Trypan Blue dye 
exclusion to detect necrotic cells (B). Here, EPA was added 
together with TNF-α as a co-treatment (EPA+TNF) or, 
alternatively EPA was administered alone for a 2 hour pre-
treatment after which it was withdrawn and replaced by 
TNF-α alone in DM (pEPA+TNF). Incubations were contin-
ued for 5 days in DM with replenishment of EPA and TNF-α 
at media changes. Data are expressed as means ± standard 
error of mean (SEM) from 3 independent experiments (*p < 
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Lipids in Health and Disease 2008, 7:24 http://www.lipidworld.com/content/7/1/24tion [41]. Peroxisome proliferator-activated receptor
(PPAR)γ is a major transcriptional regulator of lipid
metabolism whose activity can be inhibited by TNF-α,
either by altered PPARγ gene expression or by reduced
DNA binding activity. Both types of PPARγ inhibition
involve NF-κB activation [42]. Recently it has been shown
that altered expression of PPARγ in differentiating C2C12
myotubes inhibited myogenesis [43]. Interestingly, EPA
but not other -6 or -3 PUFAs induces PPARγ gene expres-
sion in human adipocytes [44].
Conclusion
In summary, the present study demonstrates that the -3
PUFA EPA exerts a protective effect on differentiating
C2C12 myotubes, attenuating the inhibitory effects of
TNF-α on indices of myogenesis and apoptosis. These
findings are consistent with reports in the literature
regarding potential mechanisms of action for EPA, but
these now require detailed investigation to clarify the
nature of the observed benefits on skeletal muscle cells.
These observations suggest for the first time that EPA may
have potential benefits in skeletal muscle regeneration.
Methods
Cell Culture
The murine skeletal muscle cell line C2C12 was obtained
from the European Centre for Animal Cell Culture
(ECACC, Porton Down, UK). C2C12 is a well established
murine model for studying skeletal muscle differentia-
tion. C2C12 myoblasts are able to undergo differentiation
into spontaneously contracting myotubes on withdrawal
of growth factors [45]. Thus, myoblasts were cultured in
low-glucose Dulbecco's Modified Eagle's medium
(DMEM) supplemented with 10% (v/v) fetal bovine
serum (FBS) (both from Lonza Biologics, Slough, UK)
containing antibiotics (10,000 units/ml penicillin G, 10
mg/ml streptomycin sulfate and 25 μg/ml amphotericin B
from Sigma-Aldrich, Poole, UK), referred to as growth
media (GM). Myoblasts were seeded at approx.104 cells/
cm2 onto uncoated tissue culture plastic flasks or multi-
well plates (Greiner Bio-One, Stonehouse, UK) for 24 h at
37°C and 5%CO2, at which point they had reached
approx. 70% confluency. At this time myoblasts were
induced to differentiate by briefly rinsing cells with PBS
and replacing GM with DMEM containing antibiotics,
supplemented with 2% (v/v) heat-inactivated horse
serum, referred to as differentiation media (DM). For pro-
liferation experiments myoblasts were maintained in GM
beyond 24 h, up to 5 days. To evaluate their effects on
myogenic differentiation, murine recombinant TNF-α
(Peprotech Ltd, London, UK) or EPA (IDS Ltd, Boldon,
Tyne & Wear, UK) were added to cell cultures directly fol-
lowing induction of differentiation. EPA was first com-
plexed with fatty-acid free bovine serum albumin (BSA)
(Sigma) as described previously [44]. Briefly, EPA stock
solutions (50 mM) were prepared in absolute ethanol and
stored at -20°C in a glass vial in the dark. Working solu-
tions were prepared by adding the required volume of
EPA stock solution to pre-warmed (37°C) DMEM con-
taining 4% (w/v) fatty acid-free BSA. Dilutions were main-
tained at 37°C for at least 1 h before their addition to cell
cultures. The final concentration of ethanol in cultures
was always below 0.1%. Myoblasts were cultured in DM
for up to 5 days after the treatment(s), receiving fresh
media after 48 h, prior to treatment(s). The dosing regi-
men for EPA and TNF-α experiments was as follows: EPA
EPA blocks baseline C2C12 apoptosisFigure 5
EPA blocks baseline C2C12 apoptosis. C2C12 cells in 
DM for 5 days were stained with Hoechst 33342 to identify 
brightly fluorescent, condensed apoptotic nuclei. Representa-
tive images are shown in (A) for cells in the presence or 
absence of 50 μM EPA with arrows indicating example apop-
totic nuclei. A semi-quantitative analysis was performed by 
calculating an apoptosis index (AI%) from these images (B). 
Quantitative analysis of caspase-8 activity (measured in rela-
tive light units, RLU) from cultures in the presence or 
absence of EPA was evaluated using the Caspase Glo-8 com-
mercial assay (C). Data are expressed as means ± standard 
error of mean (SEM) from 3 independent experiments. (*p < 
0.05 v. control). Calibration bars are 50 μm.
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change to DM and were refreshed with any media
changes; EPA treatment was given either as a pre-incuba-
tion for 2 h with EPA alone, prior to its removal and
replacement with TNF-α alone (EPA pre-treatment) or, as
a co-incubation given with TNF-α for the duration of the
experiment (EPA co-treatment).
Assessment of Myogenic Differentiation
To study the effect of TNF-α and EPA treatments on differ-
entiation of myotubes, immunocytochemistry was per-
formed. Cultures were briefly rinsed with PBS, then fixed
with ice-cold methanol for 2 min. Cells were then washed
three times with PBS for 3 min, blocked with 1% BSA in
PBS for 30 min, then incubated with 38 μg/ml of MF-20
antibody (Developmental Studies Hybridoma Bank, Uni-
versity of Iowa, USA) to detect myosin heavy chain
(MyHC) protein, at a dilution of 1:250 in 0.5% BSA/PBS
for 1 h. After washing with PBS, cells were incubated with
2 μg/ml goat anti-mouse Alexa Fluor®-546 IgG, at a dilu-
tion of 1:2000 in PBS for 1 h in the dark. After washing
with PBS, cells were counterstained with 4',6-diamidino-
2-phenylindole (DAPI). The stained cells were analysed
under a Nikon TE2000 inverted fluorescence microscope
and DAPI and MyHC images were captured with a Hama-
matsu Orca camera and merged using Image-Pro Lab v3.7
image analysis software (Nikon UK Ltd, Kingston upon
Thames, UK).
Myotube metrics were also quantified using Image-Pro
software to determine myotube diameter and a myoblast
fusion index. Average myotube diameter was evaluated as
the mean of five approximately equi-distant measure-
ments taken along the length of the myotube. For each
treatment, 10 fields of view were chosen randomly and 10
myotubes were measured in each field. A myogenic index
(MI) was also calculated to indicate myotube fusion and
the mean number of nuclei per myotube was calculated to
indicate heterogeneity of myotube size. Using 10 images
from randomly chosen microscope fields of DAPI and
MyHC stained cells for each treatment, the total number
of nuclei and the number of nuclei incorporated into
myotubes were counted. The MI was calculated as the per-
centage of nuclei incorporated into myotubes (defined as
containing at least two nuclei) relative to the total number
of nuclei. Using the same images, the myotube heteroge-
neity was calculated as the number of nuclei per myotube,
within categories of small (2–5 nuclei), medium (6–9
nuclei) and large (>10 nuclei) myotubes, expressed as a
proportion (%) of the total myotubes.
Apoptosis and Necrosis
To determine the contribution of apoptosis to cell death
during myotube differentiation, and the effects of EPA
treatment on this, cells in DM were stained with Hoechst
33342 to identify apoptotic nuclei and images captured,
as described above. Briefly, a final concentration of 1 μM
Hoechst 33342 stain (Invitrogen, Paisley, UK) was added
directly to cells in culture. After 2–10 minutes media was
removed and cells were rinsed in 1× apoptosis wash buffer
(Invitrogen) and mounted using one drop of wash buffer
and a coverslip. Analysis was performed immediately
under fluorescence microscopy. To quantify the extent of
apoptosis, an apoptosis index (AI) was calculated as
described in [46], from 6 images of randomly selected
microscope fields for each treatment. The AI was calcu-
lated as the percentage of apoptotic nuclei (brightly fluo-
rescent, condensed compared to normal) relative to the
total number of nuclei. As apoptosis during differentia-
tion of myoblasts is characterised by enhanced caspase-8
activation, the effects of TNF-α and EPA treatments on the
activity of this apoptosis marker were investigated. Cas-
pase-8 activity from cells in DM was analysed by using a
Caspase-Glo 8 assay (Promega, Southampton, UK) per-
formed according to the manufacturer's instructions. Cas-
pase-8 luminescence was quantified on a Tecan Genios
reader with Magellan software (Tecan, Reading, UK). A
cytotoxicity assay was performed following EPA treatment
EPA inhibits the TNF-α-induced caspase-8 activity associated with apop osisFigure 6
EPA inhibits the TNF-α-induced caspase-8 activity 
associated with apoptosis. The nature of the pro-apop-
totic effect of TNF-α on C2C12 myotube formation and its 
prevention by EPA were examined after 24 or 48 hours in 
DM by evaluating caspase-8 activation (measured in relative 
light units, RLU) using the Caspase Glo-8 commercial assay. 
EPA was added together with TNF-α as a co-treatment 
(EPA+TNF) or, alternatively EPA was administered alone for 
a 2 hour pre-treatment after which it was withdrawn and 
replaced by TNF-α alone in DM (pEPA+TNF). Data are 
expressed as means ± standard error of mean (SEM) from 3 
independent experiments. (*p < 0.05 v. respective control; 
#NS v. respective control).
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in DM. Quantitative analysis of cytotoxicity was made
using a Cell Titer Blue Assay kit (Promega) and under-
taken according to the manufacturer's instructions. Mor-
phological analysis of cellular necrosis was assessed by
0.4% (w/v) Trypan Blue (Sigma) vital dye staining. Myob-
lasts, seeded at a cell density of 10,000 cells per well in 6-
well multiwell plates, were cultured and induced to differ-
entiate as described above. Cellular necrosis was quanti-
fied by performing a cell count 48 hours after treatment.
The adherent cells were removed by gentle enzymatic
detachment with pre-warmed (37°C) Trypsin (Lonza)
and combined with the non-adherent cell fraction. Per-
cent viability was determined under phase-contrast micro-
scopy.
Statistical Analysis
Data is expressed as the mean ± SEM from three independ-
ent experiments. Statistical significance between two
groups/treatments was tested using unpaired Student's t
test. Statistical significance between more than two groups
was tested using one-way ANOVA. Statistical significance
was set at p < 0.05.
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